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Background: Infection with Helicobacter pylori is common worldwide and a significant cause of
upper gastrointestinal disease. Prevalence of this infection varies in different population groups
internationally. Because of the invasiveness of specimen collection for bacteriologic diagnosis and
the expense of tests such as labeled urea breath tests, serology is the most feasible means of
determining the population epidemiology of H. pylori. The aim of this study was to describe the
seroepidemiology of H. pylori infection in Australia.
Methods: H. pylori-specific ELISA for the presence of IgG antibodies was performed on a
representative sample of 2413 sera from Australia in 2002, using validated serosurveillance
methods.
Results: The overall seroprevalence of H. pylori infection in Australia was 15.1% in 2002, with no
statistical difference between genders. Seropositivity rates increased progressively with age,
ranging between 4.0% in the 1—4-year-olds and 23.3% in the 50—59-year-olds.
Conclusions: The prevalence of infection with H. pylori in Australia was lower than rates
reported in other developed countries, at 15.4%. This study provides important baseline
measurements for future preventive measures including vaccine research and development.
Further studies to determine subgroups at higher risk of infection may help target the more
susceptible populations.
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Helicobacter pylori infection has been shown to be
associated with chronic gastritis, duodenal ulceration, and
more recently the development of gastric carcinoma.1—4
Eradication of proven infection with the combined use of
antibiotics and anti-secretory therapy, usually a proton
pump inhibitor, is currently in routine use in medical
practice. However, other preventive measures such as
vaccination may play a role in the future as researchers
around the world work at developing a vaccine against
H. pylori.5—7 Background information on the epidemio-
logy of H. pylori is required to inform any prevention
programs.
Endoscopy and biopsy urease testing have the highest
sensitivity and specificity for the diagnosis of H. pylori
infection. Aside from the unfeasibility of conducting popu-
lation epidemiologic studies using this method, such a
procedure is unpleasant for patients and also carries some
risk of complications. Non-invasive diagnostic techniques
include stool culture and labeled urea breath test.8 How-
ever, these diagnostic techniques can be time-consuming
and expensive, and in particular are considered inappropri-
ate for a population-based study.9 Serological diagnostic
tests, performed on a patient’s serum, are based on the
detection of specific IgG antibodies against H. pylori.8
Immunological diagnosis does have its limitations, with
the most important being the inability to distinguish
between active H. pylori infection and previous contact,
as antibody levels persist in the blood for long periods of
time. However, these tests are a particularly useful way of
ascertaining population epidemiology and monitoring
trends over time.10
Several population-based serological studies performed
in countries around the world have been used to provide
important information towards increasing the understand-
ing of the epidemiology of H. pylori. These studies have
revealed that the overall prevalence of the infection
varies, being higher in less developed countries. For exam-
ple, a nationwide study in the asymptomatic population of
South Korea revealed a seropositive rate of 46.6%, while a
study of a small Jamaican community reported an even
higher H. pylori seropositivity of 68.8%.11,12 Developed
countries such as the USA have lower infection rates, with
one population-based study in 7465 people estimating
overall H. pylori prevalence at 32.5%. However, in this
study significant rate variations were found to exist
between different ethnic groups, with Caucasian and
black American infection rates of 26.2% and 52.7%,
respectively.13
In the past, studies on H. pylori prevalence in Australia
have only been performed in small specific subgroups. In a
Melbourne study performed on an Anglo-Celtic population,
seroprevalence was estimated at 38%, while in a
Western Australian Aboriginal population studied through
the use of urea breath tests, prevalence was 76%.14,15 To
date, a representative national population-based study
of the prevalence of H. pylori infection in Australia has
not been available. The aim of this study was to
describe the population seroepidemiology of H. pylori in
Australia.Methods
Study population
H. pylori seroprevalence was determined using a random
sample of 2413 sera (selected randomly after age-stratifica-
tion) from a bank of approximately 8000 collected from
people aged 1 to 59 years from 37 major diagnostic labora-
tories around Australia. This was a convenience sample of
sera submitted for diagnostic testing in 2002 that
would otherwise have been discarded. Sera from subjects
who were immunocompromised, had received multiple
transfusions in the past 3 months, or had submitted samples
for testing for HIV were excluded. Sera were identified at the
referring laboratory by sex, age or date of birth, residential
postcode, date of collection, and a unique identifier, to
ensure that only one sample from any subject was tested.
Sera were de-identified before testing and coded by
date of collection, state/territory of origin, and referring
laboratory.16
No other clinical information regarding the donors was
available. All testing was performed at the Centre for Infec-
tious Diseases and Microbiology (CIDM), Institute of Clinical
Pathology and Medical Research (ICPMR) at Westmead Hos-
pital, Westmead, Sydney, Australia.17
Laboratory methods
The sera collected for the study were tested for specific IgG
antibodies against H. pylori according to instructions given by
the manufacturer of a commercially available enzyme immu-
noassay, pylori DTect ELISA (Diagnostic Technology, Austra-
lia). The assay kit, with 96.4% sensitivity and 92.7%
specificity, has been validated for use in patients from both
developed and developing countries. Human serum reacts
with the native H. pylori antigens immobilized on the wells of
the microtiter plate. After the appropriate washing, any
specific antigen—antibody complex is bound by a horseradish
peroxidase (HRP)-labeled anti-human antibody conjugate
and subsequently reacted with a tetramethylbenzidine
(TMB) substrate and read at 450 nm with a spectrophot-
ometer. A positive result (>0.45 optical density) indicates
the presence of H. pylori-specific antibodies in the test sera
samples, while a negative result (<0.45 optical density)
indicates absence of these antibodies.18
Sample size and statistical analysis
Serum samples were stratified into the following age groups:
1—4, 5—9, 10—14, 15—19, 20—29, 30—39, 40—49, and 50—59
years. In all age groups the sample size was calculated to
achieve a point estimate of seroprevalence with 95% con-
fidence intervals of 3—5%, based on the expected seropre-
valence of H. pylori. The proportion seropositive and 95%
confidence intervals were calculated for each age group. An
overall weighted population seroprevalence was calculated
using the age distribution of the 2002 Australian mid-year
population estimates. Chi-square testing was used to com-
pare immunity across age groups. A p value of less than 0.05
was considered statistically significant. Analysis was con-
ducted using SPSS v13.0 and Epi Info v3.2.2.
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Table 1 Number of subjects tested and seropositivity to





% Positive 95% CI
1—4 151 4.0 1.5—8.4
5—9 150 6.0 2.8—11.1
10—14 301 8.3 5.4—12
15—19 300 10.0 6.8—14
20—29 330 12.4 9.1—16.5
30—39 381 18.4 14.6—22.6
40—49 400 22.8 18.7—27.2
50—59 400 23.3 19.2—27.7
Total 2413
CI, confidence interval.Ethical approval
Ethical approval for this study was obtained from the Human
Research Ethics Committee of the Western Sydney Area
Health Service.
Results
The serum samples from 2413 patients across Australia were
analyzed for the presence of IgG antibodies against H. pylori.
The age of the subjects ranged between 1 and 59 years and
the male to female ratio was approximately 1:1 (1203 males
and 1210 females). The number of subjects tested according
to age group is shown in Table 1. The sample size per group is
representative of the age distribution of the Australian
population in 2002.
In this Australian cohort, the overall population-weighted
prevalence of H. pylori infection in 2002 was 15.4% (95% CI
13.9—16.8%). There was no statistical difference in the
seroprevalence of H. pylori infection between males and
females with rates of 190/1203 (15.8%) and 175/1210
(14.5%), respectively ( p = 0.36). The distribution of seropo-
sitivity according to age group is shown in Figure 1.
Seroprevalence of H. pylori infection progressively
increased with age, ranging from 4.0% (95% CI 1.5—8.4%)
in the 1—4-year-old group to 23.3% (95% CI 19.2—27.7%) in the
50—59-year-olds. The most significant increase in consecu-Figure 1 Seropositivity to Helicobacter pylori in Australia as a
percentage of population, by age group (the error bars represent
the 95% confidence intervals).tive age groups of H. pylori infection occurred between the
20—29-year-old group and the 30—39-year-old group with an
increase from 12.4% (95% CI 9.1—16.5%) to 18.4% (95% CI
14.6—22.6%) ( p = 0.03).Discussion
The overall population-weighted seropositivity of H. pylori
infection in Australia was found to be 15.4%. The study
showed an association between infection and increasing
age with seropositivity rates of 4.0% in the 1—4-year-old
group rising to 23.3% in the 50—59-year-old group. Most H.
pylori seroprevalence studies performed in other countries
are based on specific subgroups of the population. Prevalence
rates across the broader population are not widely available,
especially in developed countries, and comparison with
results from our study was difficult to assess. The available
population-based serological studies show that the preva-
lence is lower than or comparable to rates found in other
developed countries, with older studies revealing rates of
15.5%, 21%, and 25% in Belgium, England, and France, respec-
tively.19,20 The prevalence rate in Australia is less than half
the rate in the USA.13 Our results are also much lower than
those from a study conducted several years ago in an Anglo-
Celtic urban population.14 This could be a difference in
sampling, a genuine difference in geographical prevalence,
or a time effect if the prevalence has been decreasing over
time with more widespread use of H. pylori eradication
therapy.
According to the World Health Organization, an effective
H. pylori vaccination is considered a potential cancer pre-
vention strategy.21 The establishment of a successful vacci-
nation regimen or that of any other form of preventive
measure for an infection requires targeting the appropriate
population and age group. This study provides baseline epi-
demiological data for this purpose.
To date, epidemiological studies seem to suggest that
transmission from person to person of H. pylori is most likely.
Supportive of this mechanism is the high concordance of
infection within families,22 as well as strong evidence indi-
cating that hygiene factors, crowding, and low economic
status also play an important role.23 This is borne out by
much higher rates in Australian Aboriginal populations, indi-
cating a greater need for prevention and treatment in this
group.15 More recent studies also implicate the role of con-
taminated water as a possible reservoir for transmission with
the presence of H. pylori found in water samples all over the
world. This, alongwith the other factors mentioned, supports
a feco-oral route as at least one of the possible mechanisms
for H. pylori transmission.24,25 Person-to-person transmission
is also supported by the fact that identical strains of H. pylori
have been isolated from members of the same family26 as
well as in people residing in the same custodial institution.27
Further knowledge of the exact transmission of H. pylori
infection is necessary to establish successful prevention
strategies, and epidemiological studies continue to provide
helpful information in this area.
Currently, guidelines for the management of dyspepsia
vary, with one of two options usually suggested. The first is a
test-and-treat option, which is preferable in populations with
a moderate to high prevalence of H. pylori infection (10%).
The seroepidemiology of Helicobacter pylori infection Australia 503The second option is to use an empiric trial of acid suppres-
sion with a proton pump inhibitor for 4—8 weeks, and this is
the recommended option in low prevalence situations.28,29 A
third option is for the prompt use of endoscopy when patients
present with dyspeptic symptoms, although most studies
suggest than this a less cost-effective approach than the
test-and-treat.30 Our study reveals a seroprevalence of H.
pylori infection of 15.4%, which is low and so the test-and-
treat option would be the recommended practice in Austra-
lia; this is supported in recent suggestions for Australian
guidelines.31 It has been suggested that the current manage-
ment of peptic ulcer disease in Australia needs to be re-
evaluated. The economic cost of anti-ulcer therapy is sig-
nificant with anti-ulcer drugs making up 6.1% of all prescrip-
tions dispensed in 1999. They were also the second most
costly group of drugs to the Australian government, consum-
ing 11.1% of the total pharmaceutical benefits scheme bud-
get. On the other hand, only 1.3% of total prescriptions in the
same year were for treatments to eradicate H. pylori even
though the benefits of eradication in the management of
peptic ulcer are well established.32
Prevention of H. pylori infection and the associated dis-
eases can occur on a number of levels. Theoretically, a
vaccine can be used to either prevent initial infection or
as a form of therapy to clear established infection. One study
suggests that the introduction of a prophylactic H. pylori
vaccine targeting infants, with 80% efficacy, lifetime protec-
tion, and 80% coverage, could reduce the prevalence of
infection from 12% to 0.7% over a 10-year period.33 The
Australian prevalence of H. pylori infection is 15.4% and
introducing a vaccine of this effectiveness during early child-
hood would theoretically produce a similar reduction in
infection rates. Further research into understanding the
mechanism of immune protection and the use of appropriate
immunogens is necessary before an H. pylori vaccine can
become a clinical possibility.34,35
On a secondary prevention level, intervention can occur
via a screening program. Some studies suggest that a com-
munity screening program for H. pylori could potentially be a
cost-saving option. The studies explain that a ‘search and
eradicate’ strategy for H. pylori would be a cost-effective
measure in reducing the incidence and mortality of gastric
cancer, but that this would largely depend upon H. pylori
prevalence of the targeted population and the efficacy of the
eradication treatment in use. They also suggest that screen-
ing would be more favorable in purely financial terms, in the
older patient cohort.36—38 Considering the greater preva-
lence of infection seen in the Aboriginal population, there
is the possibility of also targeting this group for screening and
vaccination.15 Again, further research on the cost and health
benefits of screening programs needs to be undertaken.
Our study is subject to some limitations. We used a
convenience sampling method, which could be subject to
bias. However, this method of serosurveillance has been
validated by direct comparison against a random, prospec-
tive sampling method (considered the ideal method) for
measles seroimmunity. Our method and the prospective
random sampling method showed very similar results for
measles immunity, which suggests our sampling method is
representative.39 There is no reason to believe that
our sampling method should somehow be different for H.
pylori. We have previously used this method to study theseroepidemiology of several infections, and the method has
been established as a national serosurveillance mechanism
for Australia. To limit potential bias the subjects were
enrolled from major pathology laboratories that represented
metropolitan, regional, and rural areas. Also, there was no
clinical information available with regards to the presence of
current or past H. pylori-related symptoms or diagnoses in
these patients. The sampling excluded subjects aged >60
years, which is a limitation, as the overall sampling strategy
was designed for infections that peak in early adulthood.
However, the distribution curve shows a flattening off of
prevalence after the age of 40 years. It is possible that
prevalence increases in people >60 years, but we cannot
comment on this from our data.
Seroepidemiological studies are an important source of
information, not only to describe disease patterns in certain
population groups and hence allow comparison, but also to
consider, if a vaccine were to become available, the appro-
priate subpopulations and age groups that should be tar-
geted. Findings from this study suggest that acquisition of H.
pylori infection is common in Australia and consequently
health benefits are possible with the implementation of
preventive measures aimed at decreasing the prevalence
of the infection. Although an effective vaccine is not yet
on the market, future H. pylori vaccines should ideally be
part of childhood immunization programs to maximize effec-
tiveness, as the study does show that acquisition occurs from
an early age. Screening programs may also play a role in
preventing peptic ulcers and gastric cancer. Further studies
aimed at distinguishing the more susceptible populations
through a geographical-based analysis may further aid the
development of a more cost-effective screening program or
an appropriate immunization target group should a vaccine
become available.
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